Compare Inovio Pharmaceuticals Inc (INO) vs XP Inc. Class A Common Stock (XP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs XP Inc. Class A Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while XP Inc. Class A Common Stock trades at $31.92 (market cap $15.33B). The key difference: XP Inc. Class A Common Stock is far larger — about 136.6× Inovio Pharmaceuticals Inc's market cap, and XP Inc. Class A Common Stock pays a 0.66% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and XP Inc. Class A Common Stock for 0 Days on average.
| INO | XP | |
|---|---|---|
Market Cap | $112.19M | $15.33B |
Volume | 3,201,278 | 14,214,379 |
Sector | Health | Financials |
52-Week High | $2.65 | $30.21 |
52-Week Low | $0.66 | $14.94 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $83.51M | $24.96B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About XP Inc. Class A Common Stock
XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.
Read more on XP →
